REGO PAYMENT ARCHITECTURES, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that REGO PAYMENT ARCHITECTURES, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.3K | Mar 31, 2026 |
| FY2023 | Dec 31, 2022 | $2.1K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $2.6K | Mar 31, 2023 |
| FY2020 | Dec 31, 2019 | $34.5K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $46.8K | May 27, 2020 |
| FY2017 | Dec 31, 2016 | $1.1K | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $23.5K | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $5.7K | Apr 14, 2016 |
| FY2014 | Dec 31, 2013 | $2.5K | Mar 16, 2015 |
| FY2014 | Dec 31, 2012 | $1.2K | Mar 16, 2015 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.59M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($8.93M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($16.72M) | Mar 31, 2025 |
| FY2018 | Dec 31, 2018 | ($5.97M) | Apr 1, 2019 |
| FY2018 | Dec 31, 2017 | ($4.34M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($4.82M) | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | ($7.66M) | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | ($9.65M) | Apr 14, 2016 |
| FY2014 | Dec 31, 2013 | ($15.98M) | Mar 16, 2015 |
| FY2014 | Dec 31, 2012 | ($12.04M) | Mar 16, 2015 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.52M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($7.94M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($15.79M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($15.42M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($10.07M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($3.24M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($2.38M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($5.04M) | May 27, 2020 |
| FY2018 | Dec 31, 2017 | ($3.55M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($4.29M) | Apr 2, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.33M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $3.29M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $2.92M | Mar 31, 2025 |
| FY2022 | Dec 31, 2022 | $2.06M | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $2.84M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.14M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $237.7K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $867.9K | May 27, 2020 |
| FY2018 | Dec 31, 2017 | $1.12M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $830.1K | Apr 2, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.15M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($6.97M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($7.20M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($6.26M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($5.05M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($2.19M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($1.24M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($1.31M) | May 27, 2020 |
| FY2018 | Dec 31, 2017 | ($2.70M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($2.05M) | Apr 2, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $492.3K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $3.35M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $6.60M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $6.38M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.04M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $764.8K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $785.0K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $557.3K | May 27, 2020 |
| FY2018 | Dec 31, 2017 | $477.2K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $613.3K | Apr 2, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($47.90M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($37.76M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | ($31.39M) | Mar 31, 2026 |
| FY2018 | Dec 31, 2018 | ($19.09M) | Apr 1, 2019 |
| FY2018 | Dec 31, 2017 | ($15.74M) | Apr 1, 2019 |
| FY2018 | Dec 31, 2016 | ($10.74M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2015 | ($6.66M) | Apr 2, 2018 |
| FY2016 | Dec 31, 2014 | $1.56M | Mar 31, 2017 |
| FY2015 | Dec 31, 2013 | ($122.4K) | Apr 14, 2016 |
| FY2014 | Dec 31, 2012 | $6.84M | Mar 16, 2015 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($160.16M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($147.74M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($136.11M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($117.16M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($99.55M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($98.77M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($83.13M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($78.88M) | May 27, 2020 |
| FY2018 | Dec 31, 2017 | ($72.11M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($66.70M) | Apr 2, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $158.7K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $3.01M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $6.26M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $6.01M | Apr 1, 2024 |
| FY2021 | Dec 31, 2021 | $553.1K | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $273.2K | Mar 31, 2022 |
| FY2021 | Dec 31, 2019 | $430.1K | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $10.7K | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | $7.2K | May 27, 2020 |
| FY2016 | Mar 31, 2017 | $21.0K | Mar 31, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 136.59M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 136.25M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 135.85M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 124.16M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 123.44M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 120.10M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 119.60M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 119.60M | May 27, 2020 |
| FY2018 | Dec 31, 2017 | 118.60M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 118.02M | Apr 2, 2018 |